[Skip to Content]
[Skip to Content Landing]
Article
August 1939

MAPHARSEN IN THE TREATMENT OF EARLY SYPHILISCOMPARISON OF RESULTS IN ONE HUNDRED AND EIGHTY-EIGHT CASES WITH THOSE OF THE COOPERATIVE CLINICAL GROUP

Arch Derm Syphilol. 1939;40(2):208-217. doi:10.1001/archderm.1939.01490020035005
Abstract

Opinion is almost unanimous that arsphenamine (diaminodihydroxyarsenobenzene hydrochloride) is to this day the most effective arsenical in the treatment of early syphilis. However, since its first introduction it has been apparent that because of its by-effects and the difficulty of its preparation and administration it is not a practicable drug for use by the general practitioner. Efforts have been made, and are still being made, to develop a more satisfactory arsenical. These efforts have resulted in the introduction of useful but far from ideal drugs, the most important being neoarsphenamine, silver arsphenamine and sulfarsphenamine. The need for a drug of high therapeutic efficiency, minimal toxicity and facility of preparation and administration is of vital importance for the ultimate eradication of syphilis. Among the drugs recently introduced and said to meet more closely the aforementioned criteria is mapharsen, for which the following claims1 have been made: It is a pure

First Page Preview View Large
First page PDF preview
First page PDF preview
×